Search

ObjectiveTo evaluate the impact of new reimbursement decisions for palivizumab treatment on respiratory syncytial virus (RSV) hospitalisations and the concomitant number of palivizumab prescriptions for infants aged <2 years.DesignWe compared the RSV hospitalisation rates in infants before and after implementation of new limitations during three RSV seasons 2014–2017.SettingPopulation aged <2 years at the beginning of each RSV seasons extracted from regional health systems (Lazio region, 2016, 5 898 124 inhabitants and 47 595 births).PatientsOut of 70 323 infants, 5895 (8.4%) premature babies (gestational age (GA) <37 weeks) were followed before-after Italian Medicines Agency (AIFA)-2016 limitations.InterventionIn 2016, AIFA, following the American Academy of Pediatrics guidelines, decided to limit coverage of palivizumab prophylaxis (GA ≤29 weeks).Main outcomes measuresTrend of hospitalisations by months and rate of RSV before-after new restrictions were analysed. Palivizumab prescriptions and costs for National Health Service (NHS) were considered.ResultsIn a population of 284 902 aged <2 years, the number of hospitalisations due to RSV infection was 1729. Following AIFA-2016 limitations, a reduction in the number of RSV infection-based hospitalisations from 6.3/1000 (95% CI 6.0 to 6.7) to 5.5/1000 (95% CI 5.0 to 5.9) was observed. Palivizumab showed a concomitant reduction of 48% in the number of prescriptions (saving €750 000 for the NHS). No differences of GA, age on admission or severity of RSV infection were observed.ConclusionsImplementation of the new palivizumab reimbursement criteria was not associated with an increase in the RSV hospitalisation rate for children aged <2 years despite a significant reduction in the number of palivizumab prescriptions.

Abstract: The optimal degree of lymph node dissection for gastric cancer is still matter of debate. Particularly, there are serious doubts about the reproducibility of extended lymph node dissection in western surgical units, and no studies to date have investigated factors influencing lymph node retrieval and examination during the learning curve. Univariate and multivariate retrospective analysis of 21 variables were carried out on a prospective series of 313 consecutive resections for gastric cancer performed by ten different surgeons, with lymph node retrieval and analysis performed by ten different pathologists. Endpoints were number of examined lymph nodes per patient, number of cases with inadequate nodal staging (<15 examined lymph nodes) and lymph node ratio (calculated as the absolute ratio between the number of metastatic and the number of examined lymph nodes). The number of examined lymph nodes per patient (mean ± SD 28.3 ± 14.1, median 26, range 2–78) was independently influenced by age, pN status, the type of gastric resection, the degree of lymph node dissection and single pathologist. There were 47 cases (15.0%) with incomplete nodal staging that was independently determined by the degree of lymph node dissection and by the pathologist. Lymph node ratio was independently influenced by the number of metastatic lymph nodes, the disease stage and by the histological subtype of the tumor. The role of an experienced or dedicated pathologist should not be underevaluated in western series when dealing with lymph node retrieval and examination. Lymph node ratio appeared not to be significantly influenced by the number of examined lymph nodes, being independently influenced only by the number of metastatic lymph nodes, the disease stage and by the histological subtype of the tumor. It could be therefore tested as a prognostic factor limiting the stage-migration phenomenon induced by extended lymph node dissection.

Introduction:With the increasing trend of percutaneous treatment of mitral regurgitation (MR), defining the standard of care becomes crucial. The optimal treatment of degenerative MR has to provide excellent immediate and long-term outcomes. With this study we aim to present our results of surgical repair of degenerative MR.Methods:From January 2006 to December 2017, 4195 patients (median age 57 years [IQR 46;67], 68.9% men) underwent mitral valve repair (MVr) for degenerative MR at our Institution. The outcomes were retrieved using a deterministic record linkage with the National Health System, the National Tax Register and the clinical database. The follow-up was 100% complete. A Cox regression model was used to identify factors influencing outcomes. Kaplan-Meier estimates were used to assess survival. Competing risk analysis (CIF) with death as competing risk was used to assess the incidence of major adverse cardiovascular events and mitral valve (MV) reoperation.Results:The median EF was 60% [IQR 60;65], 17.8% of patients were in atrial fibrillation and 11.6% were in NYHA ≥3. Prolapse was posterior in 70.7%, bileaflet in 20.7%, and anterior in 8.5%. A resection technique was the most used approach (60.3%), followed by edge-to-edge (26.8%) and chordal implantation (9.2%). Thirty-day mortality was 0.5% (0.24% in isolated MVr cohort). At 13 years, overall survival was 86±13% (isolated MVr 90±10% vs non-isolated MVr 78±22% p <0.0001). At multivariate analysis male sex, age, cancer, previous admission for CHF, NYHA class ≥3, complex surgery, CPB time, MR >1+ at discharge and in-hospital stay were predictors of long-term mortality. At 13 years, CIF of rehospitalization for heart failure was 5.7±0.35% and CIF of MV reoperation was 1.9±0.2%. At multivariate analysis age, prolapse of the anterior leaflet and need of second pump run independently predicted reoperation.Conclusions:Surgical MVr can be performed with very low in-hospital mortality and excellent long-term survival in high-volume centers. At 13-years, in our series the rate of rehospitalization for heart failure was very low and MV reoperation was rare. These results can be used as surgical benchmark for percutaneous treatment of degenerative MR.